• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环磷酰胺特异性的酶学基础。

The enzymatic basis of cyclophosphamide specificity.

作者信息

Hohorst H J, Bielicki L, Voelcker G

出版信息

Adv Enzyme Regul. 1986;25:99-122. doi: 10.1016/0065-2571(86)90010-5.

DOI:10.1016/0065-2571(86)90010-5
PMID:3028054
Abstract

Metabolic activation of cyclophosphamide (CP) by microsomal mixed function hydroxylases yields 4-hydroxycyclophosphamide and aldophosphamide defined as activated CP. Activated CP shows relatively high cancerotoxic selectivity in vivo and cytotoxic specificity in vitro and can be trapped rapidly by reversible reaction of hemiaminal group of the oxazaphosphorine ring with protein thiols to form protein bound activated CP (protein-S-CP). Protein-S-CP stores activated CP in a highly stable form. From pharmacokinetics of activated CP in mice after the injection of cyclophosphamide, it was calculated that about 17% of the CP dose given was stored in a pool of protein bound activated CP lasting for several days. From therapy studies with 4-(S-ethanol)-sulfido-CP in combination with excess of cysteine, it was concluded that the protein-S-CP pool may be that form of activated CP which is mainly responsible for the specific cytotoxic effects in the tumor cells. On the other hand free unbound 4-OH-CP was shown to contribute mainly to overall toxicity. No spontaneous toxicogenation of activated CP was noted under in vivo conditions. 3'-5' Exonucleases were found to hydrolyze 4-OH-CP, yielding phosphoramide mustard and acrolein as split products. Because of the low affinity of 4-OH-CP for plain 3'-5' exonucleases, it seems however unlikely that these enzymes play a major role in the antitumor effect of CP in vivo. 3'-5' Exonucleases associated to DNA polymerase like in DNA polymerase delta from rabbit bone marrow or in DNA polymerase I from E. coli are more likely candidates for 4-OH-CP toxicogenation because of the much higher specific activity with 4-OH-CP as substrate. In experiments with DNA polymerase I from E. coli, 4-OH-CP was shown to inhibit DNA polymerase activity after toxicogenation by the 3'-5' exonuclease subsite of the enzyme. This suggests an enzyme mechanism based suicide inactivation of the DNA polymerase. Because of the close spatial cooperation of the DNA polymerase and 3'-5' exonuclease subsites with primer/template a site-specific alkylation of DNA is also postulated. Thus we raised the hypothesis that cytotoxic specificity of activated CP is based on the interaction of protein-S-CP (protein bound activated CP) with DNA polymerase/3'-5' exonuclease as the target. In a P 815 mouse mast-cell tumor we determined by means of 5' AMP agarose affinity chromatography two/third of total DNA polymerase to be associated with 3'-5' exonuclease.

摘要

环磷酰胺(CP)经微粒体混合功能羟化酶进行代谢活化,产生4-羟基环磷酰胺和醛磷酰胺,二者被定义为活化型CP。活化型CP在体内显示出相对较高的癌毒性选择性,在体外具有细胞毒性特异性,并且可通过噁唑磷环的半缩醛胺基团与蛋白质硫醇的可逆反应迅速捕获,形成与蛋白质结合的活化型CP(蛋白质-S-CP)。蛋白质-S-CP以高度稳定的形式储存活化型CP。从小鼠注射环磷酰胺后活化型CP的药代动力学计算得出,给予的CP剂量中约17%储存于与蛋白质结合的活化型CP池中,并持续数天。通过4-(S-乙醇)-硫代-CP与过量半胱氨酸联合进行的治疗研究得出结论,蛋白质-S-CP池可能是活化型CP的一种形式,主要负责对肿瘤细胞的特异性细胞毒性作用。另一方面,游离的未结合4-OH-CP主要导致总体毒性。在体内条件下未观察到活化型CP的自发毒性生成。发现3'-5'核酸外切酶可水解4-OH-CP,产生磷酰胺芥和丙烯醛作为裂解产物。然而,由于4-OH-CP对普通3'-5'核酸外切酶的亲和力较低,这些酶似乎不太可能在CP体内抗肿瘤作用中发挥主要作用。与DNA聚合酶相关的3'-5'核酸外切酶,如兔骨髓中的DNA聚合酶δ或大肠杆菌中的DNA聚合酶I,更有可能是4-OH-CP毒性生成酶的候选者,因为它们以4-OH-CP作为底物时具有更高的比活性。在使用大肠杆菌DNA聚合酶I进行的实验中,4-OH-CP在被该酶 的3'-5'核酸外切酶亚位点毒性生成后,显示出抑制DNA聚合酶活性。这表明DNA聚合酶存在基于酶机制 的自杀失活。由于DNA聚合酶和3'-5'核酸外切酶亚位点与引物/模板的紧密空间协作,还推测DNA存在位点特异性烷基化。因此,我们提出了这样的假设,即活化型CP的细胞毒性特异性基于蛋白质-S-CP(与蛋白质结合的活化型CP)与作为靶点的DNA聚合酶/3'-5'核酸外切酶的相互作用。在P 815小鼠肥大细胞瘤中,我们通过5' AMP琼脂糖亲和色谱法测定,总DNA聚合酶中有三分之二与3'-5'核酸外切酶相关。

相似文献

1
The enzymatic basis of cyclophosphamide specificity.环磷酰胺特异性的酶学基础。
Adv Enzyme Regul. 1986;25:99-122. doi: 10.1016/0065-2571(86)90010-5.
2
Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3'-5' exonuclease.活化环磷酰胺:一种基于酶机制的DNA聚合酶/3'-5'核酸外切酶自杀性灭活剂。
J Cancer Res Clin Oncol. 1984;107(3):195-8. doi: 10.1007/BF01032606.
3
Enzymatic toxicogenation of "activated" cyclophosphamide by 3'-5' exonucleases.3'-5'核酸外切酶对“活化”环磷酰胺的酶促毒化作用。
J Cancer Res Clin Oncol. 1983;105(1):27-9. doi: 10.1007/BF00391828.
4
Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.噻唑烷基和全氢噻嗪基磷酰胺酯:毒性及初步抗肿瘤评估
J Cancer Res Clin Oncol. 1997;123(11-12):623-31. doi: 10.1007/s004320050116.
5
The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.环磷酰胺(NSC - 26271)的肿瘤生长抑制特异性问题:关于控制烷基化和细胞毒性活性反应的研究
Cancer Treat Rep. 1976 Apr;60(4):309-15.
6
Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro.4-硫代环磷酰胺在体外对小鼠白血病细胞的细胞毒性和DNA交联活性
Cancer Res. 1980 Nov;40(11):4216-20.
7
Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies.“活化”环磷酰胺的药代动力学及治疗效果。
Cancer. 1984 Sep 15;54(6 Suppl):1179-86. doi: 10.1002/1097-0142(19840915)54:1+<1179::aid-cncr2820541315>3.0.co;2-p.
8
Toxicity, interstrand cross-links and DNA fragmentation induced by 'activated' cyclophosphamide in yeast: comparative studies on 4-hydroperoxy-cyclophosphamide, its monofunctional analogon, acrolein, phosphoramide mustard, and nor-nitrogen mustard.“活化”环磷酰胺在酵母中诱导的毒性、链间交联和DNA片段化:对4-氢过氧环磷酰胺、其单功能类似物、丙烯醛、磷酰胺芥和去甲氮芥的比较研究
Chem Biol Interact. 1982 Mar 1;39(1):1-15. doi: 10.1016/0009-2797(82)90002-3.
9
[Intracavitary chemotherapy of S 180 ascites sarcoma in mice with 4-(S-ethanol)-sulfido-cyclophosphamide in combination with protector thiols].[用4-(S-乙醇)-硫代环磷酰胺联合保护剂硫醇对小鼠S 180腹水肉瘤进行腔内化疗]
Arzneimittelforschung. 1984;34(10):1291-8.
10
Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.环磷酰胺(NSC-26271)相关的磷酰胺氮芥——最新进展与历史回顾
Cancer Treat Rep. 1976 Apr;60(4):337-46.

引用本文的文献

1
Clinical pharmacokinetics of cyclophosphamide.环磷酰胺的临床药代动力学
Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003.
2
Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.异环磷酰胺、环磷酰胺及其代谢产物对培养的肾小管细胞的毒性作用。
Pediatr Nephrol. 1994 Apr;8(2):157-63. doi: 10.1007/BF00865466.
3
Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.癌症化疗药物研发中的理念与现实,特别提及氮杂磷三环类细胞抑制剂
J Cancer Res Clin Oncol. 1986;111(1):1-12. doi: 10.1007/BF00402768.
4
Low toxicity cancer chemotherapy by suicide inactivation of DNA polymerase alpha holoenzyme: first results with new thiazolidinyl- and perhydrothiazinyl-ethyl-N-mustard-phosphamide esters.通过DNA聚合酶α全酶的自杀失活实现低毒性癌症化疗:新型噻唑烷基和全氢噻嗪基乙基氮芥磷酰胺酯的初步结果
J Cancer Res Clin Oncol. 1988;114(3):309-11. doi: 10.1007/BF00405840.